Inasmuch as Teva’s new “low volume” formulation made its appearance after the patent challenge by NVS/MNTA on the seven Copaxone patents in the Orange Book, I think we can infer that Teva thinks the low-volume formulation will be protected by an altogether different patent.
Market Data 
Markets 
AI
